AU2001295359A1 - GnRH analogues for treatment of urinary incontinence - Google Patents

GnRH analogues for treatment of urinary incontinence

Info

Publication number
AU2001295359A1
AU2001295359A1 AU2001295359A AU9535901A AU2001295359A1 AU 2001295359 A1 AU2001295359 A1 AU 2001295359A1 AU 2001295359 A AU2001295359 A AU 2001295359A AU 9535901 A AU9535901 A AU 9535901A AU 2001295359 A1 AU2001295359 A1 AU 2001295359A1
Authority
AU
Australia
Prior art keywords
use according
medicament
anyone
symptoms
acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295359A
Other languages
English (en)
Inventor
Susi Arnold
Madeleine Hubler
Iris Reichler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Zuerich
Original Assignee
Universitaet Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Zuerich filed Critical Universitaet Zuerich
Publication of AU2001295359A1 publication Critical patent/AU2001295359A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Electrotherapy Devices (AREA)
  • Medicinal Preparation (AREA)
AU2001295359A 2000-10-30 2001-10-26 GnRH analogues for treatment of urinary incontinence Abandoned AU2001295359A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00811011 2000-10-30
EP00811011 2000-10-30
PCT/CH2001/000636 WO2002036144A1 (fr) 2000-10-30 2001-10-26 Utilisation d'analogues de gnrh dans le traitement de l'incontinence urinaire

Publications (1)

Publication Number Publication Date
AU2001295359A1 true AU2001295359A1 (en) 2002-05-15

Family

ID=8174999

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001295359A Abandoned AU2001295359A1 (en) 2000-10-30 2001-10-26 GnRH analogues for treatment of urinary incontinence

Country Status (9)

Country Link
US (2) US7498303B2 (fr)
EP (1) EP1330257B1 (fr)
JP (1) JP2004512369A (fr)
AT (1) ATE303156T1 (fr)
AU (1) AU2001295359A1 (fr)
BR (1) BR0115067A (fr)
CA (1) CA2427731A1 (fr)
DE (1) DE60113142T2 (fr)
WO (1) WO2002036144A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
UY29185A1 (es) * 2004-11-02 2006-05-31 Schering Ag Formas de dosificación oral sólidas que contienen una dosis baja de estradiol
CN101189026A (zh) * 2005-06-01 2008-05-28 辉瑞产品公司 用于治疗尿失禁的疫苗组合物及方法
EP1967202A1 (fr) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Utilisation d'antagonistes LHTH pour le traitement des symptômes de tractus urinaires faibles, en particulier la vessie hyperactive et/ou hyperactivité du détrusor
EP2266568A1 (fr) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant d'antagonistes de LHRH et d'inhibiteurs de PDE V pour le traitement des états dépendants de l'hormone sexuel
EP2266567A1 (fr) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant de Cetrorelix e d'inhibiteurs de PDE V pour le traitement des étas dépendants de l'hormone sexuel
CA2796139A1 (fr) * 2010-04-15 2011-10-20 Bayer Intellectual Property Gmbh Forme galenique orale solide a faible dose pour le ths
WO2011140607A1 (fr) * 2010-05-14 2011-11-17 Keating Charlotte L Méthode de traitement et diagnostic
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
HUE058207T2 (hu) * 2017-01-31 2022-07-28 Veru Inc Készítmények és módszerek gonadotropin felszabadító hormon (GNRH) antagonisták elnyújtott idejû felszabadítására
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434136A (en) * 1990-12-14 1995-07-18 Mathias; John R. Treatment of motility disorders with a GNRH analog
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340805A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Danazol for treatment of urinary incontinence
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
AUPN366795A0 (en) * 1995-06-20 1995-07-13 Peptide Technology Limited Formulation for preventing reproductive function
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
NZ334236A (en) * 1996-08-30 2000-06-23 Peptech Ltd Composition comprising GnRH, lecithin and stearin
US6416778B1 (en) * 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
CA2306110A1 (fr) * 1997-10-17 1999-04-29 Mochida Pharmaceutical Co., Ltd. Agent therapeutique du leiomyome uterin, comprenant du dienogeste comme principe actif
CA2329941A1 (fr) 1998-04-27 1999-11-04 Marc B. Garnick Methodes de traitement des bouffees de chaleur et de la gynecomastie
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
AU2002367425B2 (en) * 2001-12-28 2006-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for urinary disturbance

Also Published As

Publication number Publication date
DE60113142D1 (de) 2005-10-06
JP2004512369A (ja) 2004-04-22
EP1330257B1 (fr) 2005-08-31
US20090246209A1 (en) 2009-10-01
US7498303B2 (en) 2009-03-03
EP1330257A1 (fr) 2003-07-30
BR0115067A (pt) 2004-04-06
WO2002036144A1 (fr) 2002-05-10
DE60113142T2 (de) 2006-07-06
ATE303156T1 (de) 2005-09-15
US20040023878A1 (en) 2004-02-05
CA2427731A1 (fr) 2002-05-10

Similar Documents

Publication Publication Date Title
AU2001295359A1 (en) GnRH analogues for treatment of urinary incontinence
Croxatto Mechanisms that explain the contraceptive action of progestin implants for women
RU2110274C1 (ru) Способ лечения состояния, зависящего от эстрогенов яичников
Gobello Dopamine agonists, anti-progestins, anti-androgens, long-term-release GnRH agonists and anti-estrogens in canine reproduction: A review
Baerwald et al. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use
Felberbaum et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
CA2084891C (fr) Methodes et formulation a utiliser dans l'inhibition de la conception et dans le traitement des troubles gynecologiques benins
Broekmans GnRH agonists and uterine leiomyomas
Mahutte et al. Role of gonadotropin-releasing hormone antagonists in poor responders
US20100204146A1 (en) Treatment of Oestrogen Dependant Conditions in Pre-menopausal Women
Everett The control of the secretion of prolactin
CA2401022A1 (fr) Procedes de traitement des affections liees a l'hormone folliculostimulante (fsh) par le biais d'antagonistes vis-a-vis de la gonadoliberine (gnrh)
Pelican et al. Priming with progestin, but not GnRH antagonist, induces a consistent endocrine response to exogenous gonadotropins in induced and spontaneously ovulating cats
Hamdine et al. Early initiation of gonadotropin-releasing hormone antagonist treatment results in a more stable endocrine milieu during the mid-and late-follicular phases: a randomized controlled trial comparing gonadotropin-releasing hormone antagonist initiation on cycle day 2 or 6
Verspyck et al. Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial
Naem et al. Hormonal Therapies Before in Vitro Fertilization in Women with Endometriosis: The Minotaur’s Labyrinth and the Ariadne’s Thread
Kauffold et al. Synchronization of estrus and ovulation in sows not conceiving in a scheduled fixed-time insemination program
MXPA02007233A (es) Uso de la hormona foliculo estimulante en el tratamiento de la infertilidad.
Jain et al. Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive
Shaw GnRH analogues in the treatment of endometriosis—rationale and efficacy
BG65817B1 (bg) Мезопрогестини (прогестерон рецептор модулатори) за лечение и профилактика на хормонозависими доброкачествени гинекологични заболявания
Devoto et al. Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant).
Rojas et al. Studies on the antireproductive mechanisms of action of RU 486
Lemay Ovarian Suppression by GnRH Agonists
WO2024016072A1 (fr) Utilisation d'antagonistes de la gnrh chez des mammifères pour synchroniser l'émergence de vagues folliculaires